-$0.80 EPS Expected for Tricida Inc (TCDA) This Quarter

Brokerages predict that Tricida Inc (NASDAQ:TCDA) will post ($0.80) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Tricida’s earnings. The highest EPS estimate is ($0.79) and the lowest is ($0.80). The business is expected to report its next earnings results on Thursday, June 27th.

According to Zacks, analysts expect that Tricida will report full-year earnings of ($3.34) per share for the current financial year, with EPS estimates ranging from ($3.45) to ($3.22). For the next fiscal year, analysts anticipate that the business will report earnings of ($3.34) per share, with EPS estimates ranging from ($3.52) to ($3.15). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Tricida.

Tricida (NASDAQ:TCDA) last posted its earnings results on Thursday, March 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.23.

A number of research firms recently issued reports on TCDA. Zacks Investment Research raised shares of Tricida from a “hold” rating to a “buy” rating and set a $42.00 target price for the company in a research report on Saturday, March 30th. Empire increased their target price on shares of Tricida from $37.00 to $58.00 in a research report on Monday, April 1st.

TCDA traded down $0.09 on Monday, reaching $32.74. 550,800 shares of the company’s stock were exchanged, compared to its average volume of 339,722. The company has a market cap of $1.40 billion and a PE ratio of -7.06. Tricida has a twelve month low of $19.43 and a twelve month high of $40.83. The company has a debt-to-equity ratio of 0.20, a quick ratio of 16.51 and a current ratio of 16.50.

In related news, Director Orbimed Advisors Llc purchased 225,000 shares of the firm’s stock in a transaction on Wednesday, April 3rd. The stock was purchased at an average price of $36.00 per share, for a total transaction of $8,100,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Dawn Parsell Otto sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $25.00, for a total value of $50,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 151,794 shares of company stock valued at $4,407,688.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc purchased a new position in shares of Tricida during the 3rd quarter valued at approximately $33,317,000. Vanguard Group Inc. purchased a new position in shares of Tricida during the 3rd quarter valued at approximately $33,317,000. BlackRock Inc. boosted its stake in shares of Tricida by 216.4% during the 3rd quarter. BlackRock Inc. now owns 1,005,103 shares of the company’s stock valued at $30,707,000 after buying an additional 687,414 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Tricida by 17.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 686,751 shares of the company’s stock valued at $20,981,000 after buying an additional 102,514 shares during the last quarter. Finally, Opaleye Management Inc. boosted its stake in shares of Tricida by 141.2% during the 4th quarter. Opaleye Management Inc. now owns 123,000 shares of the company’s stock valued at $2,900,000 after buying an additional 72,000 shares during the last quarter. Hedge funds and other institutional investors own 69.83% of the company’s stock.

Tricida Company Profile

Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.

Featured Article: How do buyers and sellers choose a strike price?

Get a free copy of the Zacks research report on Tricida (TCDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.